Portal de Periódicos da CAPES

Isatin, an Endogenous MAO Inhibitor, as a New Biological Modulator

1999; Wiley; Volume: 5; Issue: 4 Linguagem: Inglês

10.1111/j.1527-3458.1999.tb00109.x

1527-3458

Naoya Hamaue, Masaru Minami, Masahiko Hirafuji, Mutsuko Terado, Minoru Machida, Noriko Yamazaki, Mitsuhiro Yoshioka, Akihiko Ogata, Kunio Tashiro,

Synthesis of Organic Compounds

CNS Drug ReviewsVolume 5, Issue 4 p. 331-346 Free Access Isatin, an Endogenous MAO Inhibitor, as a New Biological Modulator Naoya Hamaue, Naoya Hamaue Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, JapanSearch for more papers by this authorMasaru Minami, Corresponding Author Masaru Minami Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, JapanDr. M. Minami, Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, 061-0292 Hokkaido, Japan. Fax: 81-1332-3-1669. E-mail: minami@hoku-iryo-u.ac.jpSearch for more papers by this authorMasahiko Hirafuji, Masahiko Hirafuji Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, JapanSearch for more papers by this authorMutsuko Terado, Mutsuko Terado Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, JapanSearch for more papers by this authorMinoru Machida, Minoru Machida Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, JapanSearch for more papers by this authorNoriko Yamazaki, Noriko Yamazaki Department of Medical Technology, Hokkaido University School of Medicine, Sapporo, JapanSearch for more papers by this authorMitsuhiro Yoshioka, Mitsuhiro Yoshioka Department of Pharmacology, Hokkaido University School of Medicine, Sapporo, JapanSearch for more papers by this authorAkihiko Ogata, Akihiko Ogata Department of Neurology, Hokkaido University School of Medicine, Sapporo, JapanSearch for more papers by this authorKunio Tashiro, Kunio Tashiro Department of Neurology, Hokkaido University School of Medicine, Sapporo, JapanSearch for more papers by this author Naoya Hamaue, Naoya Hamaue Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, JapanSearch for more papers by this authorMasaru Minami, Corresponding Author Masaru Minami Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, JapanDr. M. Minami, Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, 061-0292 Hokkaido, Japan. Fax: 81-1332-3-1669. E-mail: minami@hoku-iryo-u.ac.jpSearch for more papers by this authorMasahiko Hirafuji, Masahiko Hirafuji Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, JapanSearch for more papers by this authorMutsuko Terado, Mutsuko Terado Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, JapanSearch for more papers by this authorMinoru Machida, Minoru Machida Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, JapanSearch for more papers by this authorNoriko Yamazaki, Noriko Yamazaki Department of Medical Technology, Hokkaido University School of Medicine, Sapporo, JapanSearch for more papers by this authorMitsuhiro Yoshioka, Mitsuhiro Yoshioka Department of Pharmacology, Hokkaido University School of Medicine, Sapporo, JapanSearch for more papers by this authorAkihiko Ogata, Akihiko Ogata Department of Neurology, Hokkaido University School of Medicine, Sapporo, JapanSearch for more papers by this authorKunio Tashiro, Kunio Tashiro Department of Neurology, Hokkaido University School of Medicine, Sapporo, JapanSearch for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3458.1999.tb00109.xCitations: 14AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 Anholt RR. Mitochondrial benzodiazepine receptors as potential modulators of intermediary metabolism. Trends Pharmacol Sci 1986; 6: 506– 511. 2 Armando I, Barontini M, Levin G, et al. Exercise increases endogenous urinary monoamine oxidase benzodiazepine receptor ligand inhibitory activity in normal children. J Auton Nerv Syst 1984; 11: 95– 100. 3 Armando I, Levin G, Barontini M. Stress increases endogenous benzodiazepine receptor ligand-monoamine oxidase inhibitory activity (tribulin) in rat tissues. J Neural Transm 1988; 71: 29– 37. 4 Bansal RC, Kaur P, Kiran R. Mode of interaction of isatin with rat liver alkaline phosphatase. Res Bull (Science) PU, Chandigarh 1988; 39: 71– 76. 5 Basile AS, Skolnick P. Tissue specific regulation of "peripheral-type" benzodiazepine receptor density after chemical sympathectomy. Life Sci 1988; 42: 273– 283. 6 Battacharya SK, Acharya SB. Further investigations on the anxiogenic effects of isatin. Biogen Amines 1993; 9: 453– 463. 7 Battacharya SK, Chakrabarti A, Glover V, et al. Anxiolytic activity of intraventricularly administered atrial natriuretic peptide in the rat. Neuropsyhoarmacology 1996; 15: 199– 206. 8 Battacharya SK, Clow A, Przyborowska A, et al. Effects of aromatic amino acids, pentylenetetrazol and yohimbine on isatin and tribulin activity in rat brain. Neurosci Lett 1991; 132: 44– 46. 9 Battacharya ST, Glover V, Sandler M, et al. Raised endogenous monoamine oxidase inhibitor output in postwithdrawal alcoholics: Effects of L-dopa and ethanol. Biol Psychiatry 1982; 17: 829– 836. 10 Blaschko H. Amine oxidase. In: PD Boyer, H Lardy, and K Myrback, eds. The enzymes. Vol. 8, 3rd ed. New York : Academic Press, 1973: 337– 351. 11 Chocholova L, Kolinova M. Effect of isatin on audiogenic seizures in rats and its relationship to electrographic and behavioral phenomena. Physiol Bohemoslov 1979; 28: 495– 502. 12 Chocholova L, Kolinova M. Effect of isatin (2,3 dioxyindoline) on physiological and pathological electrographic manifestations of vigilance. Physiol Bohemoslov 1981; 30: 129– 137. 13 Clow A, Glover V, Armando I, et al. New endogenous benzodiazepine receptor ligand in human urine: Identity with endogenous MAO inhibitor Life Sci 1983; 33: 735– 741. 14 Clow A, Glover V, Sandler M, et al. Increased urinary tribulin output in generalized anxiety disorder. Psychopharmacology 1988; 95: 378– 380. 15 Clow A, Glover V, Weg MW, et al. Urinary catecholamine metabolite and tribulin output during lactate infusion. Br J Psychiatry 1988; 152: 122– 126. 16 Clow A, Hussain T, Glover V, et al. Pergolide can induce soluble superoxide dismutase in rat striata. J Neural Transm 1992; 90: 27– 31. 17 Elsworth JD, Dewar D, Glover V, et al. Purification and characterization of tribulin, an endogenous inhibitor of monoamine oxidase and benzodiazepine receptor binding. J Neural Transm 1986; 67: 45– 56. 18 Glover V, Battacharya SK, Sandler M. Isatin - a new biological factor. Ind J Exp Biol 1991; 29: 1– 5. 19 Glover V, Clow A, Sandler M. Effects of dopaminergic drugs on superoxide dismutase: Implications for senescence. J Neural Transm (Suppl) 1993; 40: 37– 45. 20 Glover V, Halket JM, Watkins PJ, et al. Isatin: Identity with the purified endogenous monoamine oxidase inhibitor tribulin. J Neurochem 1988; 51: 656– 659. 21 Glover V, Medvedev A, Sandler M. Isatin is a potent endogenous antagonist of guanylate cyclase-coupled atrial natriuretic peptide receptors. Life Sci 1995; 57: 2073– 2079. 22 Glover V, Reveley MA, Sandler M. A monoamine oxidase inhibitor in human urine. Biochem Pharmacol 1980; 29: 467– 470. 23 Gorell JM, Czarnecki B. Pharmacological evidence for direct dopaminergic regulation of striatal acetylcholine release. Life Sci 1986; 38: 2239– 2246. 24 Hamaue N, Minami M, Hirafuji M, et al. Significance of isatin, an endogenous MAO inhibitor, on blood pressure control and monoamine levels. Biogen Amines 1996; 12: 395– 405. 25 Hamaue N, Minami M, Kanamaru Y, et al. Endogenous monoamine oxidate (MAO) inhibitor (tribulin-like activity) in the brain and urine of stroke-prone SHR. Biogen Amines 1992; 8: 401– 412. 26 Hamaue N, Minami M, Kanamaru Y, et al. Identification of isatin, an endogenous MAO inhibitor, in the brain of stroke-prone SHR. Biogen Amines 1994; 10: 99– 110. 27 Hamaue N, Yamazaki N, Minami M, et al. Determination of isatin, an endogenous monoamine oxidase inhibitor, in urine and tissues of rats by HPLC. Gen Pharmacol 1998; 30: 387– 391. 28 Hamaue N, Yamazaki N, Minami M, et al. Effects of isatin, an endogenous MAO inhibitor, on acetylcholine and dopamine levels in the rat striatum. Biogen Amines 1999; 15: 367– 377. 29 Hota D, Acharya SB. Studies on peripheral actions of isatin. Ind J Exp Biol 1994; 32: 710– 717. 30 Hoehn MM, Yarh MD. Parkinsonism: Onset, progression and mortality. Neurology 1967; 17: 427– 442. 31 Imperato A, Obinu MC, Casu A, et al. Evidence that neuroleptics increase striatal acetylcholine release through stimulation of dopamine D1 receptors. J Pharmacol Exp Ther 1993; 266: 557– 562. 32 Jarman J, Przylorowska A, Glover V, et al. Urinary output of endogenous monoamine oxidase inhibitor and isatin during acute migraine attack. J Neural Transm Gen Sect 1990; 84: 129– 134. 33 Knoll J. The facilitation of dopaminergic activity in the aged brain by (−)-deprenyl. A proposal for strategy to improve the quality of life in senescence. Mech Aging Dev 1985; 30: 109– 122. 34 Kumar P, Bansal RC, Mahmood A. Isatin, an inhibitor of acetylcholinesterase activity in rat brain. Biogen Amines 1993; 9: 281– 289. 35 Kumar P, Dani HM, Trehan S. Effect of isatin testicular hyaluronidase. Ind J Exp Biol 1977; 15: 655– 656. 36 Lehmann J, Langer SZ. The striatal cholinergic interneuron: Synaptic target of dopaminergic terminals Neuroscience 1983; 10: 1105– 1120. 37 Matsumoto M, Togashi H, Yoshioka M, et al. Simultaneous high-performance liquid chromatographic determination of norepinephrine, serotonin, acetylcholine and their metabolites in the cerebrospinal fluid of anaesthetized normotensive rats. J Chromatogr 1990; 52: 1– 10. 38 McIntyre IM, Norman TR. Serotonergic effects of isatin: An endogenous MAO inhibitor related to tribulin. J Neural Transm 1990; 79: 35– 40. 39 Medvedev AE, Clow A, Sandler M, et al. Isatin: A link between natriuretic peptides and monoamines J Biochem Pharmacol 1996; 52: 385– 391. 40 Mestre M, Carriot T, Neliat G, et al. PK11195, an antagonist of peripheral type benzodiazepine receptors, modulates BAYK 8644 sensitive but not β or H2-receptor sensitive voltage-operated calcium channels in the guinea pig heart. Life Sci 1986; 39: 329– 339. 41 Milgram NW, Racine RJ, Nellis P, et al. Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci 1990; 47: 415– 420. 42 Minami M, Senjo M, Togashi H, et al. Kidney glutathione S-transferase activity and kidney monoamine oxidase activity in stroke cases of SHRSP. Biogen Amines 1988; 5: 517– 526. 43 Muller M, Schramek J. Combined application of propranolol and local anesthetics: Enhanced anticonvulsant action. Biomed Biochim Acta 1989; 4: 333– 336. 44 Nilsson OG, Leanza G, Bjkölund A. Acetylcholine release in the hippocampus: Regulation by monoaminergic afferents as assessed by in vivo microdialysis. Brain Res 1992; 584: 132– 140. 45 Ogata A, Tashiro K, Nukuzuma S, et al. A rat model of Parkinson's disease induced by Japanese encephalitis virus. J Neurovirol 1997; 3: 141– 147. 46 Ohue T, Koshimura K, Akiyama Y, et al. Regulation of acetylcholine release in vivo from rat hippocampus by monoamines as revealed by novel column-switching HPLC with electrochemical detection. Brain Res 1992; 572: 340– 344. 47 Oxenkrug G, McIntyre I. Stress-induced synthesis of melatonin: Possible involvement of the endogenous monoamine oxidase inhibitor (tribulin). Life Sci 1985; 37: 1743– 1746. 48 Parvez H, Parvez S. The effects of metopirone and adrenalectomy on the regulation of the enzymes monoamine oxidase and catechol-O-methyl transferase in different brain regions. J Neurochem 1973; 20: 1011– 1020. 49 Paxinos G, Wason C. The Rat Brain in Streotaxic Coordinates. 2nd ed. New York : Academic Press Inc., 1980. 50 Peturson H, Bhattacharya SK, Glover V, et al. Urinary monoamine oxidase inhibitor and benzodiazepine withdrawal. Br J Psychiatry 1982; 140: 7– 10. 51 Sandler M. The emergence of tribulin. Trends Pharmacol Sci 1982; 3: 471– 472. 52 Satyan KS, Rai A, Jaiswal AK, et al. Isatin, a putative anxiogenic endocoid, induces memory dysfunction in rats. Ind J Exp Biol 1995; 33: 576– 579. 53 Scatton B. Further evidence for the involvement of D2 but not D1 dopamine receptors in dopaminergic control of striatal cholinergic transmission. Life Sci 1992; 31: 2883– 2890. 54 Sethy VH, Van Woert MH. Regulation of striatal acetylcholine concentration by dopamine receptors. Nature 1974; 251: 529– 530. 55 Singh B, Sharma R, Sareen K, et al. Isatin enzyme interaction V. Activation of rat liver acid phosphatase. Enzyme 1977; 22: 256– 261. 56 Stadler H, Lloyd KG, Gadea-Ciria M, et al. Enhanced striatal acetylcholine release by chlorpromazine and its reversal by apomorphine. Brain Res 1973; 55: 476– 480. 57 Stoof JC, Drukarch B, DeBoer P, et al. Regulation of the activity of striatal cholinergic neurons by L-DOPA. Neuroscience 1992; 47: 755– 770. 58 Susheela I, Singh B, Dani HM, et al. Enzyme inhibition by isatin I. Inhibition of rat liver xanthine oxidase. Enzymology 1969; 37: 325– 334. 59 Tozawa Y, Ueki A, Manabe S, et al. Stress-induced increase in urinary isatin excretion in rats-reversal by both dexamethasone and a-methyl-p-tyrosine. Biochem Pharmacol 1998; 56: 1041– 1046. 60 Ueki A, Willoughby J, Glover V, et al. Endogenous urinary monoamine oxidase inhibitor excretion in Parkinson's disease and other neurological disorders. J Neural Transm 1989; 1: 263– 268. 61 Watkins P, Clow A, Glover V, et al. Isatin, regional distribution in rat brain and tissues. Neurochem Int 1990; 17: 321– 323. 62 Wedzong K, Limberger N, Spath L, et al. Acetylcholine release in rat nucleus accumbens is regulated through dopamine D2 receptor. Naunyn-Schmiedeberg's Arch Pharmacol 1988; 338: 250– 255. 63 Wilkins MR, Nunez DJ, Wharton J. The natriuretic peptide family: Turning hormones into drugs. J Endocrinol 1993; 137: 347– 359. 64 Yang HYT, Neff NH. The monoamine oxidases of brain: Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 1974; 189: 733– 740. 65 Yumiler AT. The effect of isatin (tribulin) on metabolism of indoles in the rat brain and pineal: In vitro and in vivo studies. Neurochem Res 1990; 15: 95– 100. Citing Literature Volume5, Issue4December 1999Pages 331-346 ReferencesRelatedInformation